Surgery of skeletal metastases in 306 patients with prostate cancer

نویسندگان

  • Rüdiger J Weiss
  • Jonathan A Forsberg
  • Rikard Wedin
چکیده

PURPOSE Skeletal metastases are common in patients with prostate cancer, and they can be a source of considerable morbidity. We analyzed patient survival after surgery for skeletal metastases and identified risk factors for reoperation and complications. PATIENTS AND METHODS This study included 306 patients with prostate cancer operated for skeletal metastases during 1989-2010. Kaplan-Meier analysis was used to calculate survival. Cox multiple regression analysis was performed to study risk factors, and results were expressed as hazard ratios (HRs). RESULTS The median age at surgery was 72 (49-94) years. The median survival after surgery was 0.5 (0-16) years. The cumulative 1-, 2-, and 3-year survival after surgery was 29% (95% CI: 24-34), 14% (10-18), and 8% (5-11). Age over 70 years (HR 1.4), generalized metastases (HR 2.4), and multiple skeletal metastases (HR 2.3) resulted in an increased risk of death after surgery. Patients with lesions in the humerus (HR 0.6) had a lower death rate. The reoperation rate was 9% (n = 31). The reasons for reoperation were deep wound infection (n = 10), hematoma (n = 7), material (implant) failure (n = 3), wound dehiscence (n = 3), increasing neurological symptoms (n = 2), prosthetic dislocation (n = 2), and others (n = 4). INTERPRETATION This study involves the largest reported cohort of patients operated for skeletal lesions from prostate cancer. Our survival data and analysis of predictors for survival help to set appropriate expectations for the patients, families, and medical staff.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Diagnostic uncertainty of isolated skull lesion in prostate cancer- Role of SPECT/CT

Skeletal involvement is the second most common site of metastases after lymph nodal metastases in patients with prostate cancer. The skeletal metastases from prostate cancer are osteoblastic in nature and show increased tracer avidity on the bone scan. Focal tracer avid lesion in skeleton especially in skull requires the careful examination by further investigation. The patients with skull meta...

متن کامل

Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases

Introduction: The aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153Sm-EDTMP in patients with intractable metastatic bone pain. Methods: Sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the...

متن کامل

Evaluation of Strontium-89 in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [Persian]

Treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. Bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. A good palliative treatment must be complete, free from side effects and fast; Thus we decided to evaluate Strontium-89 (89Sr) effectivity for palliation of breast and prostate cancer b...

متن کامل

Effectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases

Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...

متن کامل

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223

A 76-year-old man with symptomatic bone metastases from castrationresistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or rel...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 83  شماره 

صفحات  -

تاریخ انتشار 2012